These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 23838604

  • 1. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.
    Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, Anand SS, Zuvich RL, Bradford Y, Ross S, Nakamura Y, Ritchie M, Brown NJ.
    Pharmacogenet Genomics; 2013 Sep; 23(9):470-8. PubMed ID: 23838604
    [Abstract] [Full Text] [Related]

  • 2. Pharmacogenetic markers for antihypertensive drug-related adverse reactions.
    Cerda A, Hirata RD, Hirata MH.
    Pharmacogenomics; 2013 Nov; 14(15):1819-20. PubMed ID: 24386648
    [No Abstract] [Full Text] [Related]

  • 3. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators.
    Lancet; 2008 Aug 16; 372(9638):547-53. PubMed ID: 18707986
    [Abstract] [Full Text] [Related]

  • 4. Telmisartan, ramipril, or both in patients at high risk for vascular events.
    ONTARGET InvestigatorsPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada. yusufs@mcmaster.ca, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.
    N Engl J Med; 2008 Apr 10; 358(15):1547-59. PubMed ID: 18378520
    [Abstract] [Full Text] [Related]

  • 5. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Yu LT, Zhu J, Tan HQ, Wang GG, Teo KK, Liu LS.
    Chin Med J (Engl); 2011 Jun 10; 124(12):1763-8. PubMed ID: 21740829
    [Abstract] [Full Text] [Related]

  • 6. [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
    Düsing R, Nitschmann S.
    Internist (Berl); 2008 Sep 10; 49(9):1137-40. PubMed ID: 18665340
    [No Abstract] [Full Text] [Related]

  • 7. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
    Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, Commerford P, Dyal L, Schumacher H, Pogue J, Paolasso E, Holwerda N, Chazova I, Binbrek A, Young J, Yusuf S, ONTARGET and TRANSCEND Investigators.
    Lancet Neurol; 2011 Jan 10; 10(1):43-53. PubMed ID: 20980201
    [Abstract] [Full Text] [Related]

  • 8. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H, ONTARGET/TRANSCEND Investigators.
    Am Heart J; 2004 Jul 10; 148(1):52-61. PubMed ID: 15215792
    [Abstract] [Full Text] [Related]

  • 9. Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema.
    Straka B, Nian H, Sloan C, Byrd JB, Woodard-Grice A, Yu C, Stone E, Steven G, Hartert T, Teo KK, Pare G, McCarty CA, Brown NJ.
    J Allergy Clin Immunol Pract; 2013 Jul 10; 1(5):468-73.e1-4. PubMed ID: 24565618
    [Abstract] [Full Text] [Related]

  • 10. Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.
    Anderson C.
    J Int Med Res; 2005 Jul 10; 33 Suppl 1():50A-57A. PubMed ID: 16222900
    [Abstract] [Full Text] [Related]

  • 11. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T.
    Am J Cardiol; 2003 May 22; 91(10A):28G-34G. PubMed ID: 12781906
    [Abstract] [Full Text] [Related]

  • 12. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV, Dass EE.
    Indian J Pharmacol; 2015 May 22; 47(2):148-52. PubMed ID: 25878372
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF, ONTARGET and TRANSCEND Investigators.
    Circulation; 2011 Mar 15; 123(10):1098-107. PubMed ID: 21357827
    [Abstract] [Full Text] [Related]

  • 16. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema.
    Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ.
    Pharmacogenet Genomics; 2010 Sep 15; 20(9):532-6. PubMed ID: 20625347
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
    Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S, ONTARGET/TRANSCEND Investigators.
    Circulation; 2009 Oct 06; 120(14):1380-9. PubMed ID: 19770395
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.